Blacksmith Medicines Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for FG-2101, a Novel Antibiotic Targeting LpxC
FDA’s designation provides FG-2101 with an additional five years of market exclusivity and priority review SAN DIEGO, Oct. 13, 2025 /PRNewswire/ — Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing medicines targeting metalloenzymes, announced today that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) and the Fast Track Designation under the Generating Antibiotic Incentives Now





















